Key takeaways
- £20K-30K Standard NICE Technology Appraisal QALY threshold applied to both cannabidiol (TA614) and fenfluramine (TA808) — neither drug used the ultra-rare HSS route
- £9-16M Estimated total NHS annual Dravet drug spend across cannabidiol and fenfluramine combined (400-500 UK patients)
- £2K-4K Annual per-patient cost of the mandatory Fintepla Cardiac Monitoring Scheme (FCMS), reimbursed by UCB under PAS
Both NICE-commissioned Dravet therapies cleared standard Technology Appraisal with confidential PAS — but the treatment algorithm is now closed to new entrants without a significant clinical edge.
NICE TA614 (2019, cannabidiol/Epidiolex) and TA808 (2022, fenfluramine/Fintepla) were both appraised through the standard Technology Appraisal process, not the NHS England Highly Specialised Services (HSS) route reserved for ultra-rare conditions — meaning the ordinary NICE cost-effectiveness bar of £20,000-£30,000/QALY applied to both assessments, not the £100,000-£300,000/QALY threshold used for HSS-designated technologies. Cannabidiol's TA614 model was built on a 38.9% seizure-frequency reduction versus placebo on top of clobazam, at a post-PAS NHS cost estimated at £15,000-£25,000 per patient per year. Fenfluramine's TA808 model was built on a 62% seizure reduction (STUDIO 1) versus CBD background therapy, at an estimated post-PAS cost of £30,000-£50,000 per patient per year including cardiac monitoring. Both PAS agreements remain confidential, and both cleared NICE's standard TA cost-effectiveness bar: the same bar any new Dravet entrant would need to clear, not a materially higher one.
Fenfluramine also carries a mandated cardiac monitoring burden: the Fintepla Cardiac Monitoring Scheme (FCMS) requires echocardiography every 6 months, monthly blood pressure monitoring, and annual ECG at paediatric epilepsy HSS-designated centres, administered by NHS cardiology, at an estimated cost of £2,000-£4,000 per patient per year — a cost UCB reimburses under PAS terms and which NICE TA808 accepted as consistent with favourable cost-effectiveness against the standard TA threshold. Combined, NHS annual Dravet drug spend across an estimated 400-500 UK patients totals £9-16M: cannabidiol for the 50-60% of patients on first-line therapy, fenfluramine for the 30-40% of CBD inadequate responders who step up. That is a modest budget for standard TA commissioning, but the algorithm is now closed; any new Dravet therapy must demonstrate significant additional seizure reduction or a meaningful tolerability advantage over CBD-plus-fenfluramine background therapy to secure a NICE recommendation.
UK Dravet Syndrome agent NHS commissioning summary
| Drug (Brand / INN) | NICE Appraisal / Pathway | NHS Commissioning Status | Monitoring / Access Requirement | Estimated NHS Cost | Key Payer Risk |
|---|---|---|---|---|---|
| Epidiolex (cannabidiol) | NICE TA614 (2019), standard Technology Appraisal | NHS HSS-designated centres; dominant UK Dravet SoC | Standard follow-up only | £15,000-25,000/patient/year post-PAS | New entrants must beat the 38.9% seizure-reduction benchmark |
| Fintepla (fenfluramine) | NICE TA808 (2022), standard Technology Appraisal | NHS HSS-designated centres; second-line after CBD | FCMS: echo every 6 months, monthly BP, annual ECG | £30,000-50,000/patient/year post-PAS, incl. monitoring | Cardiac monitoring cost baked into PAS; new agent must match or reduce this burden |
Sources: NICE TA614 and TA808 Final Appraisal Determinations; NHS England HSS Dravet commissioning specification (service delivery designation, not the appraisal route); FCMS programme details (UCB UK).
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- Why did NICE route both cannabidiol (TA614) and fenfluramine (TA808) through standard Technology Appraisal rather than the ultra-rare HSS pathway, and what does that mean for a new Dravet entrant? • Standard TA vs HSS QALY threshold analysis (£20K-30K vs £100K-300K) • NICE TA614/TA808 Final Appraisal Determination review • PAS discount modelling required to clear the standard TA bar
- What cardiac monitoring and safety-scheme costs does the NHS bear for fenfluramine under the Fintepla Cardiac Monitoring Scheme, and how are they factored into NICE's cost-effectiveness model? • FCMS structure and per-patient monitoring cost (echo, BP, ECG cadence) • UCB PAS reimbursement mechanics • NICE TA808 acceptance of monitoring burden within the standard TA cost-effectiveness threshold
- With NHS total annual Dravet drug spend at £9-16M and the treatment algorithm considered closed, what clinical or tolerability bar must a new therapy clear to displace CBD-plus-fenfluramine background therapy? • NHS Dravet budget sizing by agent • competitive displacement threshold analysis • NICE precedent for incremental-benefit requirements against an established two-drug algorithm
What's inside
-
1 · UK Dravet Syndrome NHS Commissioning Overview 4 pp
- Why NHS annual Dravet drug spend across an estimated 400-500 UK patients totals £9-16M combined for cannabidiol and fenfluramine
- How 50-60% of patients remain on first-line cannabidiol while 30-40% of CBD inadequate responders step up to fenfluramine
-
2 · NICE Standard TA — TA614 (Cannabidiol) Cost-Effectiveness and Commissioning 5 pp
- Why cannabidiol's TA614 model, built on a 38.9% seizure-frequency reduction versus placebo, cleared NICE's standard £20,000-30,000/QALY bar
- How a post-PAS NHS cost of £15,000-25,000 per patient per year makes cannabidiol the benchmark any new entrant must beat
-
3 · NICE Standard TA — TA808 (Fenfluramine) Cost-Effectiveness and FCMS Monitoring 5 pp
- Why fenfluramine's TA808 model, built on a 62% seizure reduction in STUDIO 1, cleared the same standard TA bar as cannabidiol, not a higher one
- How the Fintepla Cardiac Monitoring Scheme's £2,000-4,000 per-patient annual cost is reimbursed by UCB under PAS terms
-
4 · NHS Dravet Annual Spend — Patient Volume and Budget Modelling 4 pp
- How an estimated 400-500 UK patients split across cannabidiol first-line and fenfluramine second-line therapy drives the £9-16M total NHS spend
- Why this modest budget size still required both drugs to demonstrate favourable cost-effectiveness against the standard NICE TA threshold
-
5 · Competitive Displacement Threshold for New Dravet Entrants 5 pp
- Why the Dravet treatment algorithm is now closed, meaning a new therapy must show significant additional seizure reduction over CBD-plus-fenfluramine
- How the mandatory FCMS cardiac monitoring burden sets a tolerability bar any new entrant must match or reduce to compete
-
6 · Sources and Methodology 3 pp
- What NICE Final Appraisal Determinations, NHS England HSS commissioning specifications and FCMS programme documents underpin every figure in this brief
- Why NHS HSS commissioning designation is a service-delivery structure, distinct from the standard Technology Appraisal route both drugs actually used
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx Dravet Syndrome Payer & HTA is built for market access, HEOR, and pricing teams navigating NICE's standard Technology Appraisal route, FCMS monitoring economics, and the closed NHS treatment algorithm in the UK Dravet market. Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, payer focus (NICE HSS/TA, PAS, FCMS/monitoring), and commercial question.
- 2. Scoping callAXLRx analyst confirms payer scope, NICE pathway analysis, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
This assessment is built from NICE Technology Appraisal Final Appraisal Determinations (TA614, TA808), NHS England Highly Specialised Services commissioning specifications, and manufacturer-published cardiac monitoring programme documentation.
Key sources: NICE TA614 (cannabidiol, 2019) and TA808 (fenfluramine, 2022) Final Appraisal Determinations; NHS England HSS Dravet commissioning budget analysis; Fintepla Cardiac Monitoring Scheme (FCMS) programme details, UCB UK.
- NICE standard TA QALY threshold verified against NICE TA614 and TA808 Final Appraisal Determinations; confirmed neither drug used the HSS route directly on NICE.org.uk
- NHS annual Dravet spend estimate verified against NHS England HSS Dravet commissioning budget analysis
- FCMS cardiac monitoring cost and cadence verified against UCB UK FCMS programme documentation
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only: NICE technology appraisals for cannabidiol and fenfluramine, NHS England highly specialised service commissioning budget analysis, and the manufacturer-run cardiac monitoring scheme documentation. No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered assessment.
Customisation Can I tailor the assessment to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target geography, key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions, such as additional payer markets, pipeline agent profiles, or country-specific deep-dives, can be added to any standard assessment. Commission via the intake form to start.